{"filing":{"accession_number":"0001214659-26-007903","cik":"0001643918","ticker":"BDRX","company_name":"Biodexa Pharmaceuticals Plc","form":"6-K","filing_date":"2026-06-30","report_date":null,"primary_document":"i6292636k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1643918/000121465926007903/i6292636k.htm"},"events":[{"id":14908,"run_id":13291,"accession_number":"0001214659-26-007903","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This press release announces a $3.5 million registered direct offering and concurrent private placement of pre-funded warrants and warrants by Biodexa Pharmaceuticals. The offering includes 282,952 ADSs at $2.85 per ADS in the registered portion, plus pre-funded warrants and multiple series of unregistered warrants (Series M, N, and O) to purchase over 2.2 million ADSs in aggregate. The private placement components and unregistered warrant issuances are classic dilutive equity financing mechanisms, particularly material for a clinical-stage biopharmaceutical company raising capital for development programs.","company_name":"Biodexa Pharmaceuticals Plc","ticker":"BDRX","filing_date":"2026-06-30","form":"6-K","submitted_at":null,"items":[{"id":12487,"accession_number":"0001214659-26-007903","item_number":"EX-99.1","item_title":"ex99_1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This press release announces a $3.5 million registered direct offering and concurrent private placement of pre-funded warrants and warrants by Biodexa Pharmaceuticals. The offering includes 282,952 ADSs at $2.85 per ADS in the registered portion, plus pre-funded warrants and multiple series of unregistered warrants (Series M, N, and O) to purchase over 2.2 million ADSs in aggregate. The private placement components and unregistered warrant issuances are classic dilutive equity financing mechanisms, particularly material for a clinical-stage biopharmaceutical company raising capital for development programs.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-30T13:19:39.162143+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12487,"accession_number":"0001214659-26-007903","item_number":"EX-99.1","item_title":"ex99_1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This press release announces a $3.5 million registered direct offering and concurrent private placement of pre-funded warrants and warrants by Biodexa Pharmaceuticals. The offering includes 282,952 ADSs at $2.85 per ADS in the registered portion, plus pre-funded warrants and multiple series of unregistered warrants (Series M, N, and O) to purchase over 2.2 million ADSs in aggregate. The private placement components and unregistered warrant issuances are classic dilutive equity financing mechanisms, particularly material for a clinical-stage biopharmaceutical company raising capital for development programs.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-30T13:19:39.162143+00:00","company_name":"Biodexa Pharmaceuticals Plc","ticker":"BDRX","filing_date":"2026-06-30"}]}